Suchergebnisse - "Sgherza, Nicola"

PubPharm (99)

1

Antibody Response to Breakthrough SARS-CoV-2 Infection in "Booster" Vaccinated Patients with Multiple Myeloma According to B/T/NK Lymphocyte Absolute Counts and anti-CD38 Treatments

enthalten in: Mediterranean journal of hematology and infectious diseases | 2024

von Sgherza, N. | Mestice, A. | Larocca, A. | +1

2

Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic : Results from the EPICOVIDEHA registry

enthalten in: Hematological oncology | 2024

von Musto, P. | Salmanton-García, J. | Sgherza, N. | +84

3

Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma : a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials

enthalten in: Haematologica | 2024

von Gentile, M. | Vigna, E. | Palmieri, S. | +44

4

Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses : a single center analysis of 64 cases

enthalten in: Annals of hematology | 2024

von Sgherza, N. | Curci, P. | Rizzi, R. | +7

5

Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic : Results from the EPICOVIDEHA registry

enthalten in: Hematological Oncology | 2024

von Musto, P. | Salmanton‐García, J. | Sgherza, N. | +84

6

Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients : subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese"

enthalten in: Leukemia & lymphoma | 2023

von Mele, G. | Di Renzo, N. | Cascavilla, N. | +21

7

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial

enthalten in: EClinicalMedicine | 2023

von Zamagni, E. | Oliva, S. | Gay, F. | +28

8

Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)

enthalten in: Mediterranean journal of hematology and infectious diseases | 2023

von Sgherza, N. | Curci, P. | Rizzi, R. | +5

9

SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance

enthalten in: HemaSphere | 2022

von Sgherza, N. | Di Gennaro, D. | Curci, P. | +15

10

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

enthalten in: Hematological oncology | 2022

von Bruzzese, A. | Derudas, D. | Galli, M. | +57

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]